Last $36.58 USD
Change Today +0.47 / 1.30%
Volume 1.4M
ZTS On Other Exchanges
New York
As of 8:04 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

zoetis inc (ZTS) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/6/14 - $37.97
52 Week Low
04/15/14 - $28.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZOETIS INC (ZTS)

zoetis inc (ZTS) Details

Zoetis Inc. is engaged in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. It operates through four segments: United States, Europe/Africa/Middle East, Canada/Latin America, and Asia/Pacific. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines that are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy, and dermatology products, as well as reproductive products. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

9,800 Employees
Last Reported Date: 03/26/14
Founded in 1952

zoetis inc (ZTS) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $825.0K
Group President and Executive Vice President
Total Annual Compensation: $605.0K
Executive Vice President and President of U.S...
Total Annual Compensation: $400.0K
President of Research & Development and Execu...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

zoetis inc (ZTS) Key Developments

Zoetis Inc. Declares Fourth Quarter 2014 Dividend on Common Stock, Payable on December 2, 2014

The board of directors of Zoetis Inc. declared a fourth quarter dividend payable to holders of the company’s common stock of $0.072 per share. The dividend is to be paid on December 2, 2014, to holders of record on November 5, 2014.

Zoetis Unveils Antibody Detection Test for Johne's Disease in Cattle

Zoetis announced that it has unveiled a new SERELISA ParaTB Ab Mono Indirect assay kit to screen for the detection of antibodies to Johne's Disease in cattle. Matthew Krecic, DVM, MS, MBA, DACVIM, Senior Technical Services Manager of US Diagnostics, the company, said the test uses an indirect immunoenzymatic technique to detect Mycobacterium avium, subspecies paratuberculosis (M.ParaTB) antibodies in samples of cattle serum and plasma. Results are available in less than 75 minutes, giving producers an economical, convenient way to help monitor their herds for the presence of this chronic, contagious, and fatal disease.

Zoetis Granted Conditional License for Porcine Epidemic Diarrhea Vaccine

Zoetis Inc. announced that the U.S. Department of Agriculture (USDA) has granted a conditional license for a vaccine to help fight porcine epidemic diarrhea virus (PEDv) in pigs. The two-dose inactivated vaccine, licensed for use in healthy pregnant female pigs (sows and gilts), is designed to help them develop antibodies which can be transmitted to their newborn piglets. Zoetis anticipates the vaccine will be available to veterinarians and pig farmers in September 2014. The vaccine is given as a 2 mL intramuscular (IM) injection to sows or gilts prior to farrowing (giving birth). Two doses given three weeks apart are recommended, with the second dose given two weeks pre-farrowing. Previously vaccinated sows should receive a single dose given two weeks before farrowing. On average, female pigs farrow twice each year. In order to receive the conditional license, the vaccine was shown to be safe in a field safety study, and a reasonable expectation of efficacy was demonstrated. Zoetis is working to complete the studies necessary to obtain full licensure in the U.S.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZTS:US $36.58 USD +0.47

ZTS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €105.85 EUR -0.81
ImmuCell Corp $4.60 USD +0.01
Parnell Pharmaceuticals Holdings Pty Ltd $4.57 USD -0.13
Valneva SE €4.28 EUR -0.10
Virbac SA €160.80 EUR -2.10
View Industry Companies

Industry Analysis


Industry Average

Valuation ZTS Industry Range
Price/Earnings 34.8x
Price/Sales 4.0x
Price/Book 14.5x
Price/Cash Flow 31.2x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOETIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at